Research chemical is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
HIR/IRC "HIR" is a GE designation for a lamp with an infrared reflective coating. Since less heat escapes, the filament burns hotter and more efficiently. The Osram designation for a similar coating is "IRC".
== Clinical relevance == In normal dopamine and serotonin (5-HT) neurotransmitter synthesis, AADC is not the rate-limiting step in either reaction. However, AADC becomes the rate-limiting step of dopamine synthesis in patients treated with L-DOPA (such as in Parkinson's disease), and the rate-limiting step of serotonin synthesis in people treated with 5-HTP (such as in mild depression or dysthymia). AADC is inhibited by carbidopa outside of the blood brain barrier to inhibit the premature conversion of L-DOPA to dopamine in the treatment of Parkinson's. In humans, AADC is also the rate-limiting enzyme in the formation of trace amines. Aromatic L-amino acid decarboxylase deficiency is associated with various symptoms as severe developmental delay, oculogyric crises and autonomic dysfunction. The molecular and clinical spectrum of AAAC deficiency is heterogeneous. The first case of AADC deficiency was described in twin brothers 1990. Patients can be treated with dopamine agonists, MAO inhibitors, and pyridoxine (vitamin B6). Clinical phenotype and response to treatment is variable and the long-term and functional outcome is unknown. To provide a basis for improving the understanding of the epidemiology, genotype–phenotype correlation and outcome of these diseases their impact on the quality of life of patients, and for evaluating diagnostic and therapeutic strategies a patient registry was established by the noncommercial International Working Group on Neurotransmitter Related Disorders (iNTD).
At one point, Israeli commandos boarded helicopters prepared to fly into Iraq, but the mission was called off after a phone call from US defense secretary Dick Cheney, reporting on the extent of coalition efforts to destroy Scuds and emphasizing that Israeli intervention could endanger US forces. In addition to the attacks on Israel, 47 Scud missiles were fired into Saudi Arabia, and one missile was fired at Bahrain and another at Qatar. The missiles were fired at both military and civilian targets. One Saudi civilian was killed, and 78 others were injured. No casualties were reported in Bahrain or Qatar. The Saudi government issued all its citizens and expatriates with gas masks in the event of Iraq using missiles with warheads containing chemical weapons. The government broadcast alerts and 'all clear' messages over television to warn citizens during Scud attacks. On 25 February 1991, a Scud missile hit a US Army barracks of the 14th Quartermaster Detachment, out of Greensburg, Pennsylvania, stationed in Dhahran, Saudi Arabia, killing 28 soldiers and injuring over 100. A subsequent investigation found that the assigned Patriot missile battery had failed to engage due to the loss of significance effect in the onboard computer's floating point calculations compounding over 100 hours of consecutive use, shifting the range gate position far enough to lose contact with the Scud during tracking action.
=== Corticosteroids === Glucocorticoids, such as prednisone or methylprednisolone, are sometimes used in the treatment of ankylosing spondylitis to manage acute flares and provide short-term relief from inflammation and symptoms. They are powerful anti-inflammatory medications that can help reduce pain, swelling, and stiffness associated with AS. However, glucocorticoids are generally not recommended for long-term use. They are more commonly used as localized injections when someone with AS has a temporary pain flare in a particular joint or area.
== Pests and diseases == Witches' broom (Moniliophthora perniciosa) is the most prominent disease that affects cupuaçu trees. It affects the entire tree and can result in significant loss of yields and even tree death if left untreated. Regular pruning is recommended to reduce the severity of this disease in cupuaçu plantings. Cupuaçu supports the butterfly herbivore, "lagarta verde", Macrosoma tipulata (Hedylidae), which can be a defoliator.
Sources: en.wikipedia.org
Treatment of anorexia involves restoring the patient back to a healthy weight, treating their underlying psychological problems, and addressing underlying maladaptive behaviors, often with forms of talking therapy; some examples of clinically proven therapies include cognitive behavioral therapy or Maudsley family therapy, an approach where parents assume responsibility for feeding their child. A daily low dose of olanzapine has been shown to increase appetite and assist with some weight gain in patients. Psychiatrists may prescribe patients with anorexia nervosa forms of medication to better manage anxiety or depression, these being disorders often commonly associated with the disorder. However, medications are not considered a cure for anorexia nervosa: such pathways rather address underlying causes for the disorder, which often assist in recovery of it by allowing the individual to have a clearer and healthier mental state to understand the complications of anorexia nervosa. It does not assist those who do not have any other related mental conditions that affect their ability to do so. It has been proven to assist in the recovery of other eating disorders, such as bulimia nervosa and binge eating disorder. In severe cases, individuals may require to be fed by nasogastric tube to restore weight and healthy nutritional levels by force. Evidence for benefit from nasogastric tube feeding is unclear; some individuals recover after the first incident of admission, while others have recurring treatments over many years: sometimes indefinitely.
=== Agriculture === Similar to other areas, Ningxia has seen a gradual decline of its peasant population due to rural–urban migration. Despite this, the great majority (62.8 percent) was still agricultural at the time of the survey. Animal husbandry is important for the regional economy. In the main pastoral county, Yanchi, it is even the leading industry when specified for the primary sector. The dominant grazing animals are sheep and goat. In the (semi-)pastoral regions, herders engage in a mixed sedentary farming operation of dryland agriculture and extensive animal husbandry, while full nomadic pastoralism is no longer practiced. Since a cattle breeding plan was implemented in 2002, the province has become one of China's main dairy production areas. Ningxia is the principal region of China where wolfberries are grown. Other specialties of Ningxia are licorice, products made from Helan stone, fiddlehead and products made from sheepskin. Ningxia wines are a promising area of development. The Chinese authorities have given approval to the development of the eastern base of the Helan Mountains as an area suitable for wine production. Several large Chinese wine companies including Changyu and Dynasty Wine have begun development in the western region of the province. Together they now own 20,000 acres of land for wine plantations and Dynasty has ploughed 100 million yuan into Ningxia. In addition, the major oil company China Petroleum and Chemical Corporation has founded a grape plantation near the Helan Mountains.
== Works == Tew has co-authored 2 books focusing on carcinogenesis and cancer treatment strategies. He co-wrote Preclinical and Clinical Modulation of Anticancer Drugs with Peter J. Houghton and Janet A. Houghton, providing an analysis of theoretical and practical approaches to the design and implementation of modulation principles. His collaborative work with Gary D. Kruh, Basic Science of Cancer, explored the advancements in cancer research, covering interrelated topics such as tumor suppressor genes, apoptosis, transcriptional regulation, pharmacology of anticancer drugs, cytogenetic techniques, oncogenes, and signal transductions. Tew co-edited books from the series Advances in Cancer Research alongside Paul B. Fisher, where they provided reviews on diverse cancer research topics. In a review published in the Journal of Medicinal Chemistry, Thomas J. Bardos wrote about the series, "This rapidly growing series of volumes containing many excellent, highly informative, in-depth reviews on a variety of timely topics relating to cancer research has always been most representative in the areas of tumor biology and immunology."
== Cell signaling == Cell signaling involves many different processes and proteins. One of the most studied cell signaling phenomena involving proline is the interactions with p53 and prolyl isomerases, specifically Pin1. The protein p53, along with p63 and p73, are responsible for ensuring that alterations to the genome are corrected and for preventing the formation and growth of tumors. proline residues are found throughout the p53 proteins and without the phosphorylation and isomerization of specific Serine/Threonine-Proline motifs within p53, they cannot exhibit control over their target genes. The main signalling processes that are affected by p53 are apoptosis and cell cycle arrest, both of which are controlled by specific isomerization of the prolines in p53.
=== Economic issues === Sanders focuses on economic issues such as income and wealth inequality, poverty, raising the minimum wage, universal healthcare, canceling all student debt, making public colleges and universities tuition-free by taxing financial transactions, establishing a 32-hour work week, and expanding Social Security benefits by eliminating the cap on the payroll tax on incomes above $250,000. He has become a prominent supporter of laws requiring companies to give their workers parental leave, sick leave, and vacation time, noting that nearly all other developed countries have such laws. He also supports legislation that would make it easier for workers to join or form a trade union. He opposed the Troubled Asset Relief Program and has called for comprehensive financial reforms, such as breaking up "too big to fail" financial institutions, restoring Glass–Steagall legislation, reforming the Federal Reserve Bank, and allowing the Post Office to offer basic financial services in economically marginalized communities. Believing greater emphasis is needed on labor rights and environmental concerns when negotiating international trade agreements, Sanders voted against and has long spoken against NAFTA, CAFTA, and PNTR with China. He has called them a "disaster for the American worker", saying that they have resulted in American corporations moving abroad.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.